# PREcision Medicine through IntErrogation of Rna in the kidnEy (PREMIERE)

> **NIH NIH U01** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 · $655,448

## Abstract

ABSTRACT
The kidney has developed a complex, three-dimensional architecture to serve its key functions, including
excretion of waste substances, maintenance of the internal balance for fluid and salt, blood pressure control,
and hormonal function. Understanding the roles of the individual renal cell types and cell states in these
processes in health and disease is critical to develop novel targeted therapies. Extensive studies lead by this
investigative group and others have started to identify molecular disease mechanism in renal biopsy tissues
and helped to develop novel disease markers and therapies. The PREcision Medicine through IntErrogation of
Rna in the kidnEy (PREMIERE) Network has brought investigators from three leading biomedical research
institutions with diverse, complementary expertise together. Our team has an established track record in
working jointly to develop state of the art approaches in molecular analysis of renal disease. We will continue
to perform high-quality, high-throughput single cell RNA sequencing on research biopsies from the Kidney
Precision Medicine Project and advance the technology for deeper sequence coverage, reduce cost, use
smaller biopsy portions without data loss so that additional technologies can be employed across KPMP, in a
robust and reproducible manner. These single cell profiles will be linked to the disease states of the patients.
Key signatures associated with specific cells and diseases will be extracted and localized in the spatial context
of the kidney using specific, highly multiplexed RNA staining techniques. Additionally, we will employ cutting
edge spatial transcriptomic technology to map cell clusters to their local environment for an added dimension
of disease understanding. To this end the PREMIERE investigators will work closely with the tissue
procurement sites and the Central Hub of the KPMP, using their 20 years of experience in team science, so
that at the end of the KPMP funding cycle, novel cell type specific treatment targets are identified fueling the
therapeutic pipelines of the future.

## Key facts

- **NIH application ID:** 10513837
- **Project number:** 2U01DK114907-06
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Nir Hacohen
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $655,448
- **Award type:** 2
- **Project period:** 2017-09-15 → 2027-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10513837

## Citation

> US National Institutes of Health, RePORTER application 10513837, PREcision Medicine through IntErrogation of Rna in the kidnEy (PREMIERE) (2U01DK114907-06). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10513837. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*